Non-invasive staging of metastasis by precision MRI
Ended Project Grant Awarded Last action
- Award ID
- R44CA268403
- Recipient
-
Inlighta Biosciences L.L.C. UEI KCSBM7ASMA34
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,908,443
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Place of performance
- Georgia, USA
Award details come from USAspending.gov.
Description
- Abstract
- This sbir application will develop an improved contrast agent for precision staging through early and accurate detection of pancreatic ductal adenocarcinoma (PDAC) liver metastasis. We have created an innovative platform technology using a new class of protein-based MRI contrast agents (PROCAS) for contrast-enhanced MRI. We have developed an effective approach to generate protein contrast agents against an array of molecular biomarkers including collagen I (PROCA32.collagen). This extracellular matrix protein is highly expressed in the tumor microenvironment and its expression levels and crosslinking increase upon progression. PROCA32.collagen exhibits 10- to 50-fold increase in both R1 and R2 relaxivities, compared to clinically-approved GD3+ contrast agents, resulting in exceptional imaging capability that can discern heterogeneous tissue signals via a dual MR imaging methodology. PROCA32.collagen has strong collagen binding affinity, enables early detection of small liver metastases
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1 | |
| Amendment | $1 | |
| Amendment | $1 | |
| Amendment | $1 | |
| Amendment | $1 | |
| Amendment | $954,219 | |
| Original award | $954,219 |
Show all 16
Quick answers
Who received award R44CA268403?
R44CA268403 was awarded to Inlighta Biosciences L.L.C. by National Cancer Institute (National Institutes of Health) on September 23, 2022.
How much is award R44CA268403 worth?
$3,908,443 has been obligated on R44CA268403.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award